Phase 3 Vaccine Clinical Trials
10 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–10 of 10 trials
Recruiting
Phase 3
A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years
Varicella (Chickenpox)Chickenpox Vaccine
GC Biopharma Corp474 enrolled1 locationNCT07054099
Recruiting
Phase 3
Shingrix in Renal Transplant Recipients
Kidney FailureKidney TransplantationKidney Failure, Chronic+2 more
University of Colorado, Denver132 enrolled4 locationsNCT04128189
Recruiting
Phase 3
Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination
Pneumococcal Vaccines
Vaxcyte, Inc.720 enrolled30 locationsNCT07425392
Recruiting
Phase 3
RSV Vaccine in Transplant Recipients
Immune SuppressionVaccine Response ImpairedRespiratory Syncytial Virus Infections
University Health Network, Toronto100 enrolled1 locationNCT06593210
Recruiting
Phase 3
A Study to Evaluate the Immunogenicity and Safety of an EV71 Vaccine (Envacgen®) in Children Aged 6 to <10 Years Compared to Children Aged 2 to <6 Years
Enterovirus 71 Inactivated Vaccine
Medigen Vaccine Biologics Corp.378 enrolled3 locationsNCT07178522
Recruiting
Phase 3
A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine
Pneumococcal InfectionsPneumococcal Vaccines
Beijing Minhai Biotechnology Co., Ltd500 enrolled3 locationsNCT06608199
Recruiting
Phase 3
Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer
Urinary Bladder NeoplasmsTreatment OutcomeImmunotherapy, Active+3 more
Fujian Medical University Union Hospital76 enrolled1 locationNCT06441110
Completed
Phase 3
Human Papilloma Virus (HPV) Vaccination in Special Risk Groups
Special Risk Groups
1. Paediatric Rheumatalogical Disease
2. Inflammatory Bowel Disease
3. Acute Lymphoblastic Leukaemia
4. Solid Organ Transplant Recipients (kidney and liver)
5. Chronic Renal Disease
6. Bone Marrow Transsplant
The response to the HPV vaccine will be studied within these 6 special risk groups.
National Health and Medical Research Council & Clinical Centre of Research Excellence(NHMRC CCRE) in Childhood and Adolescent Immunisation100 enrolled1 locationACTRN12609000571279
Not Yet Recruiting
Phase 3
Long Term Immunogenicity of the JE Vaccine IC51
Prophylactic Vaccine against Japanese Encephalitis
Intercell AG600 enrolled1 locationACTRN12605000681651
Not Yet Recruiting
Phase 3
Safety and Tolerability Study of the JE Vaccine IC51
Prophylactic Vaccine against Japanese Encephalitis
Intercell AG600 enrolled1 locationACTRN12605000680662